Axsome Therapeutics Stock Net Income
| AXSM Stock | USD 185.17 2.85 1.52% |
As of the 29th of January, Axsome Therapeutics shows the Downside Deviation of 1.6, risk adjusted performance of 0.1435, and Mean Deviation of 1.91. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 185.17 per share. Given that Axsome Therapeutics has jensen alpha of 0.6371, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Axsome Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 16.3835 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -258.5 M | -245.6 M | |
| Net Loss | -258.5 M | -245.6 M | |
| Net Loss | -168.4 M | -160 M | |
| Net Loss | (6.89) | (6.55) | |
| Net Income Per E B T | 1.15 | 1.16 |
Axsome | Net Income | Build AI portfolio with Axsome Stock |
Latest Axsome Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Axsome Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Axsome Therapeutics financial statement analysis. It represents the amount of money remaining after all of Axsome Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Axsome Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (287.22 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Axsome Net Income Regression Statistics
| Arithmetic Mean | (96,342,907) | |
| Coefficient Of Variation | (110.18) | |
| Mean Deviation | 91,893,614 | |
| Median | (30,965,464) | |
| Standard Deviation | 106,150,620 | |
| Sample Variance | 11268T | |
| Range | 285M | |
| R-Value | (0.92) | |
| Mean Square Error | 1767.9T | |
| R-Squared | 0.85 | |
| Slope | (19,413,490) | |
| Total Sum of Squares | 180287.3T |
Axsome Net Income History
Other Fundumenentals of Axsome Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Axsome Therapeutics Net Income component correlations
Axsome Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Axsome Therapeutics is extremely important. It helps to project a fair market value of Axsome Stock properly, considering its historical fundamentals such as Net Income. Since Axsome Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Axsome Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Axsome Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Axsome Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Axsome Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Axsome Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Axsome Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Axsome Therapeutics or generate 0.0% return on investment in Axsome Therapeutics over 90 days. Axsome Therapeutics is related to or competes with Nuvalent, Abivax SA, Cytokinetics, Rhythm Pharmaceuticals, Arrowhead Pharmaceuticals, Crispr Therapeutics, and Vaxcyte. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervou... More
Axsome Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Axsome Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Axsome Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.6 | |||
| Information Ratio | 0.1623 | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 4.2 |
Axsome Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axsome Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Axsome Therapeutics' standard deviation. In reality, there are many statistical measures that can use Axsome Therapeutics historical prices to predict the future Axsome Therapeutics' volatility.| Risk Adjusted Performance | 0.1435 | |||
| Jensen Alpha | 0.6371 | |||
| Total Risk Alpha | 0.3153 | |||
| Sortino Ratio | 0.3423 | |||
| Treynor Ratio | (1.70) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1435 | |||
| Market Risk Adjusted Performance | (1.69) | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 1.2 | |||
| Downside Deviation | 1.6 | |||
| Coefficient Of Variation | 542.13 | |||
| Standard Deviation | 3.38 | |||
| Variance | 11.43 | |||
| Information Ratio | 0.1623 | |||
| Jensen Alpha | 0.6371 | |||
| Total Risk Alpha | 0.3153 | |||
| Sortino Ratio | 0.3423 | |||
| Treynor Ratio | (1.70) | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 4.2 | |||
| Downside Variance | 2.57 | |||
| Semi Variance | 1.45 | |||
| Expected Short fall | (2.54) | |||
| Skewness | 4.4 | |||
| Kurtosis | 28.18 |
Axsome Therapeutics Backtested Returns
Axsome Therapeutics appears to be very steady, given 3 months investment horizon. Axsome Therapeutics secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of risk over the last 3 months. By analyzing Axsome Therapeutics' technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please makes use of Axsome Therapeutics' Mean Deviation of 1.91, downside deviation of 1.6, and Risk Adjusted Performance of 0.1435 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of -0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.
Auto-correlation | 0.84 |
Very good predictability
Axsome Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Axsome Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Axsome Therapeutics price movement. The serial correlation of 0.84 indicates that around 84.0% of current Axsome Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.84 | |
| Spearman Rank Test | 0.73 | |
| Residual Average | 0.0 | |
| Price Variance | 218.22 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Axsome Therapeutics reported net income of (287.22 Million). This is 184.16% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 150.3% higher than that of the company.
Axsome Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axsome Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics of similar companies.Axsome Therapeutics is currently under evaluation in net income category among its peers.
Axsome Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Axsome Therapeutics from analyzing Axsome Therapeutics' financial statements. These drivers represent accounts that assess Axsome Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Axsome Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.0B | 1.4B | 3.1B | 3.6B | 3.3B | 3.4B | |
| Enterprise Value | 2.9B | 1.4B | 3.0B | 3.4B | 3.1B | 3.2B |
Axsome Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Axsome Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Axsome Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Axsome Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Axsome Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Axsome Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Axsome Therapeutics' value.| Shares | Eventide Asset Management, Llc | 2025-06-30 | 725.7 K | Wellington Management Company Llp | 2025-06-30 | 725 K | Alethea Capital Management, Llc | 2025-06-30 | 667.4 K | T. Rowe Price Associates, Inc. | 2025-06-30 | 612.7 K | Ubs Group Ag | 2025-06-30 | 595.5 K | Amvescap Plc. | 2025-06-30 | 571.5 K | Man Group Plc | 2025-06-30 | 525.1 K | Partner Fund Management Lp | 2025-06-30 | 483.1 K | Norges Bank | 2025-06-30 | 468.3 K | Vanguard Group Inc | 2025-06-30 | 3.9 M | Blackrock Inc | 2025-06-30 | 3.8 M |
Axsome Fundamentals
| Return On Equity | -2.75 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 9.2 B | ||||
| Shares Outstanding | 50.41 M | ||||
| Shares Owned By Insiders | 15.69 % | ||||
| Shares Owned By Institutions | 77.01 % | ||||
| Number Of Shares Shorted | 2.71 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 126.17 X | ||||
| Price To Sales | 16.89 X | ||||
| Revenue | 385.69 M | ||||
| Gross Profit | 515.6 M | ||||
| EBITDA | (272.6 M) | ||||
| Net Income | (287.22 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 192.96 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 1.47 X | ||||
| Cash Flow From Operations | (128.41 M) | ||||
| Short Ratio | 4.49 X | ||||
| Earnings Per Share | (4.66) X | ||||
| Target Price | 210.19 | ||||
| Number Of Employees | 816 | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 9.48 B | ||||
| Total Asset | 568.5 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.96 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 568.5 M |
About Axsome Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.